COVID-19 Herd Immunity in the Absence of a Vaccine: An Irresponsible Approach
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread rapidly throughout the human population, the concept of “herd immunity” has attracted the attention of both decision-makers and the general public. In the absence of a vaccine, this entails that a large proportion of the population will be infected to develop immunity that would limit the severity and/or extent of subsequent outbreaks. We argue that adopting such an approach should be avoided for several reasons. There are significant uncertainties about whether achieving herd immunity is possible. If possible, achieving herd immunity would impose a large burden on society. There are gaps in protection, making it difficult to shield the vulnerable. It would de
Abstract
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread rapidly throughout the human population, the concept of “herd immunity” has attracted the attention of both decision-makers and the general public. In the absence of a vaccine, this entails that a large proportion of the population will be infected to develop immunity that would limit the severity and/or extent of subsequent outbreaks. We argue that adopting such an approach should be avoided for several reasons. There are significant uncertainties about whether achieving herd immunity is possible. If possible, achieving herd immunity would impose a large burden on society. There are gaps in protection, making it difficult to shield the vulnerable. It would de
참고문헌 (30)
- Yousef Alimohamadi, "Estimate of the Basic Reproduction Number for COVID-19: A Systematic Review and Meta-analysis", 예방의학회지, 53(3), pp.151~157 (2020), 대한예방의학회[DOI]
- Ghisolfi S, "Predicted COVID-19 fatality rates based on age, sex, comorbidities and health system capacity", BMJ Glob Health, 5, pp.e003094~ (2020)
- "Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19)" (2020)[URL]
- Carfì A, "Persistent symptoms in patients after acute COVID-19", JAMA, 324, pp.603~605 (2020)
- Zubair AS, "Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019 : a review", JAMA Neurol, 77, pp.1018~1027 (2020)
- Stewart DJ, "Renal dysfunction in hospitalised children with COVID-19", Lancet Child Adolesc Health, 4, pp.e28~e29 (2020)
- Mitrani RD, "COVID-19 cardiac injury : implications for long-term surveillance and outcomes in survivors", Heart Rhythm, 17, pp.1984~1990 (2020)
- Romero-Sánchez CM, "Neurologic manifestations in hospitalized patients with COVID-19 : the ALBACOVID registry", Neurology, 95, pp.e1060~e1070 (2020)
- "The prevalence of long COVID symptoms and COVID-19 complications" (2020)[URL]
- Cirulli E, "Long-term COVID-19 symptoms in a large unselected population", medrxiv https:, doi.org, pp.10.1101, 2020.10.07.20208702[DOI]
- Roberts CM, "COVID-19 : a complex multisystem disorder", Br J Anaesth, 125, pp.238~242 (2020)
- Wu LP, "Duration of antibody responses after severe acute respiratory syndrome", Emerg Infect Dis, 13, pp.1562~1564 (2007)
- Edridge AW, "Seasonal coronavirus protective immunity is short-lasting", Nat Med, 26, pp.1691~1693 (2020)
- To KK, "COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing", Clin Infect Dis, pp.ciaa1275~ (2020)
- "Also reinfections in the Netherlands and Belgium"[URL]
- Katzelnick LC, "Antibody-dependent enhancement of severe dengue disease in humans", Science, 358, pp.929~932 (2017)
- "COVID-19 reinfection tracker" (2020)[URL]
- Xiao AT, "Profile of specific antibodies to SARSCoV-2 : the first report", J Infect, 81, pp.147~178 (2020)
- Long QX, "Clinical and immunological assessment of asymptomatic SARS-CoV-2infections", Nat Med, 26, pp.1200~1204 (2020)
- Dan JM, "Immunological memory to SARS-CoV-2 assessed for greater than six months after infection", bioRxiv 2020. doi: https:, doi. org, pp.10.1101, 2020.11.15.383323
- Le Bert N, "SARS-CoV-2-specific T cell immunity in cases of COVID-19and SARS, and uninfected controls", Nature, 584, pp.457~462 (2020)
- Mateus J, "Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans", Science, 370, pp.89~94 (2020)
- Sekine T, "Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19", Cell, 183, pp.158~168 (2020)
- Thieme CJ, "Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients", Cell Rep Med, 1, pp.100092~ (2020)
- "Some are winning - some are not: which countries do best in beating COVID-19?"[URL]
- "Number of cases of covid-19 in Sweden - data up to and including the previous day are published weekdays"[URL]
- "Coronavirus pandemic (COVID-19)"[URL]
- Buss LF, "Three-quarters attack rate of SARSCoV-2 in the Brazilian Amazon during a largely unmitigated epidemic", Science, 371, pp.288~292 (2021)
- Sabino EC, "Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence", Lancet, 397, pp.452~455 (2021)
- "SARS-CoV-2 mink-associated variant strain – Denmark" (2020)[URL]